Onterris (ONT) Q2 2026 earnings review
Guidance Slashed Amid Strategic Review and Poison Pill
The hyper-growth narrative from 2025 came to a sudden halt in Q2 as Onterris's revenue plunged 20% YoY to $186.7M. Management slashed FY26 revenue guidance by a massive $105M at the midpoint, abandoning their Q1 defense that delayed work would simply shift to the second half. Instead, lower emergency response and pass-through revenues have permanently impaired the year. Despite the top-line shock, aggressive cost optimization pushed Adjusted EBITDA margins up to 17.1%. Overshadowing the financials, the Board adopted a 'poison pill' rights plan and launched a strategic review to evaluate acquisition interest following an undisclosed accumulation of shares.
🐂 Bull Case
Despite a $48M YoY revenue drop, Consolidated Adjusted EBITDA margin improved to 17.1% (up from 16.9%). The core consulting business is highly profitable even when episodic emergency work dries up.
The Board's strategic review explicitly mentions evaluating 'acquisition interest.' With a rights plan in place to prevent a stealth takeover, shareholders could benefit from a competitive buyout premium.
🐻 Bear Case
Management's Q1 narrative that delayed projects would be captured in H2 proved false. Slashing the FY26 revenue guide from $870M to $765M (midpoint) destroys visibility and trust in the organic growth engine.
Operating cash flow in 1H26 swung to a negative $5.5M (from positive $27.4M in 1H25). Reaching the implied $70-$80M H2 target to hit annual conversion goals carries immense execution risk.
⚖️ Verdict: 🔴
Bearish. Stable margins cannot mask a $105M guidance cut and negative 1H cash flow. The abrupt poison pill and strategic review suggest management is fighting external pressures from a weakened operational position.
Key Themes
Guidance Cut Contradicts 'Transitory' Narrative
Reversing. In Q1, management insisted a revenue miss was merely 'transitory' and that work had shifted to H2. Q2 shattered that defense: FY26 revenue guidance was slashed from $870M to $765M at the midpoint. The $105M downward revision is blamed on lower pass-through revenue ($35-$55M), lower emergency response ($35-$45M), and other shortfalls ($15-$25M). This data point directly contradicts the positive underlying growth narrative pushed earlier this year.
Strategic Review & Poison Pill
Stable. The Board adopted a one-year stockholder rights plan to thwart 'significant and undisclosed accumulation' of Onterris shares. Concurrently, they launched a strategic review to evaluate acquisition interest and other alternatives. This defensive maneuver indicates the company is actively in play, and management is either fighting for standalone control or negotiating a premium exit.
Emergency Response Flips to a Drag
Reversing. The environmental emergency response business flipped from a massive growth driver in FY25 to a severe anchor in FY26. Q2 emergency response revenue declined by $37.7M YoY, wiping out nearly all top-line momentum. The episodic and unpredictable nature of this segment makes year-over-year comparables highly volatile and obscures core visibility.
Margin Expansion via Cost Discipline
Accelerating. Despite the 20% revenue plunge, Consolidated Adjusted EBITDA margins improved from 16.9% in 25Q2 to 17.1% in 26Q2. This demonstrates successful cost optimization and a favorable shift toward higher-margin projects. The company remains confident in achieving a ~15.5% margin for the full year, a 150 basis point expansion over FY25.
H2 Cash Flow Reliance
Decelerating. 1H26 net cash used in operating activities was $5.5M, a drastic reversal from the $27.4M generated in 1H25. While management points to a $27.7M Q1 bonus payout as a factor, they are banking on generating $70-$80M in operating cash flow in H2 to meet their 60% conversion target. This heavy back-half reliance leaves little room for error.
State and International Regulatory Macro Tailwinds
Stable. The underlying macro demand for core testing and consulting remains insulated from U.S. federal policy shifts. Demand continues to be structurally driven by stringent, compliance-driven state-level regulations (such as in CO, TX, CA) and international mandates like EU methane rules for exporters.
Water Technology Innovation
Stable. The company is actively leveraging its proprietary water treatment intellectual property, expanding its patent portfolio well beyond PFAS. By adapting this technology to treat broader industrial contaminants like landfill leachate, Onterris is capturing a much larger addressable market via a high-margin, integrated technology-as-a-service model.
Other KPIs
Calculated as $27.9M on $125.6M in revenue, up slightly from 21.8% in 25Q2. This segment absorbed the brunt of the $46.2M revenue decline (mostly emergency response), yet proactive cost discipline allowed margins to accelerate.
Decelerating from 29.1% in 25Q2. While revenue only dipped slightly ($61.1M vs $62.8M), the lower utilization rate on high fixed costs resulted in margin compression. However, management noted strong client demand accelerating into H2.
Increased from 2.8x in Q1, primarily due to lower trailing 12-month earnings and $30M in share repurchases executed in H1. Management still expects to end the year at approximately 2.5x, contingent on the aggressive H2 cash flow ramp.
Guidance
Reversing. Slashed significantly from the prior $840.0-$900.0 million range. At the $765M midpoint, this implies an ~8% YoY decline compared to FY25's $830.5M, completely unwinding previous assumptions of low double-digit organic growth.
Decelerating from the previous $125.0-$130.0M guide, but still Accelerating YoY vs FY25's $116.2M. The $118.5M midpoint implies a 15.5% margin, representing a 150 basis point expansion over the prior year, highlighting the success of cost-cutting.
Decelerating YoY. While representing a sequential improvement from Q2's $186.7M, the $200M midpoint is an 11% drop compared to 25Q3's record $224.9M. The EBITDA margin is guided at 17.0%-18.0%.
Accelerating sequentially. After burning $5.5M in H1, management left the annual conversion target unchanged, committing to a massive $70-$80M operating cash generation in the back half of the year.
Key Questions
Activist Pressure Details
Can you characterize the nature of the 'undisclosed accumulation' of shares that triggered the poison pill? Are you in active dialogue with this party, or is this a purely preemptive defense?
Pass-Through Revenue Evaporation
You lowered annual revenue guidance by $35-$55M strictly due to 'pass-through revenue.' Did a specific large subcontractor contract unexpectedly end, or does this reflect a structural change in how clients are funding projects?
H2 Cash Flow Bridge
Generating $70-80M in operating cash flow in H2 implies a drastic step-up from the negative $5.5M in H1. Beyond the absence of the Q1 bonus payout, what specific working capital releases give you confidence in hitting this target?
Emergency Response Normalization
With the $35-$45M cut to emergency response guidance, are we finally at a baseline trough for this segment, or could it normalize even further downward in a low-event environment?